相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
Sandhya Khurana et al.
CLINICAL THERAPEUTICS (2019)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
ROLE OF MAST CELLS IN ATHEROSCLEROSIS: A CLASSICAL INFLAMMATORY DISEASE
E. Spinas et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2014)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan Long et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Omalizumab and the risk of malignancy: Results from a pooled analysis
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
分享论文
